MedTrace Logo

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

NCT03267498 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-12

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well nivolumab and chemoradiotherapy works in treating patients with stage II-IVB nasopharyngeal cancer. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells. Chemoradiotherapy is the combination of chemotherapy and radiation therapy and may prevent the cancer from spreading when combined with nivolumab. Giving nivolumab and chemoradiotherapy may work better in treating patients with stage II-IVB nasopharyngeal cancer.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

Nivolumab

Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.

DRUG

Cisplatin

Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.

RADIATION

Radiation Therapy

2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday

Sponsors & Collaborators

Principal Investigators

  • Sue S Yom, MD, PhD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-14
Primary Completion
2024-10-31
Completion
2024-10-31
FDA Drug
Yes

Countries

  • United States
  • Singapore

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03267498 on ClinicalTrials.gov